Production of Naturally Compressed Screening Arrays
Poster Jul 08, 2011
Steven A Trim.
Animal venoms and toxins are a rich source of novel biologics with several making the progression from tool to therapeutic such as FDA approved Integrilintm (Eptifibatide) (Millennium pharmaceuticals)1 derived from Rattlesnake venom for unstable angina. Several other animal toxins are in various stages of research for such applications as antimicrobials, analgesics, thrombosis and even cancer; contortrostatin (copper head, agkistrodon contortrix, venom) reduces metastasies from breast carcinomas2. Venoms are complex mixtures of peptides, enzymes and smaller biomolecules amongst others, thus representing a vast library of tools. Traditional screening methodologies required single compounds in single wells but with the advent of compressed screening plates, much higher density screens can be run with fewer reagents and in shorter time frames. The Venom Discovery ArrayTM (VDATM) is a naturally compressed hit-to-tool screening plate produced by Venomtech Limited that makes use of natures compressed libraries (venoms) and phylogenetic diversity allowing for maximum discovery potential. These VDA’s can be targeted to specific disease areas with many related species or maximum diversity with up to 96 species from a wide group of animals including snakes, spiders, scorpions and insects.
(1) Philips and Scarborough, (1997), The American Journal of Cardiology 80(4): 11-20. (2) Mohit Trikha, Yves A. De Clerck, and Francis S. Markland, (1994) Cancer research. 54:4993-4998.
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018